PDF(Pubmed)
Abstract：
BACKGROUND: Patients with type 2 diabetes often face early tubular injury, necessitating effective treatment strategies. This study aimed to evaluate the impact of the SGLT2 inhibitor empagliflozin on early tubular injury biomarkers in type 2 diabetes patients with normoalbuminuria.
METHODS: A randomized controlled clinical study comprising 54 patients selected based on specific criteria was conducted. Patients were divided into an intervention group (empagliflozin, n = 27) and a control group (n = 27) and treated for 6 weeks. Tubular injury biomarkers KIM-1 and NGAL were assessed pre- and post-treatment.
RESULTS: Both groups demonstrated comparable baseline characteristics. Post-treatment, fasting and postprandial blood glucose levels decreased similarly in both groups. The intervention group exhibited better improvements in total cholesterol, low-density lipoprotein, and blood uric acid levels. Renal function indicators, including UACR and eGFR, showed greater enhancements in the intervention group. Significant reductions in KIM-1 and NGAL were observed in the intervention group.
CONCLUSIONS: Treatment with empagliflozin in type 2 diabetes patients with normoalbuminuria led to a notable decrease in tubular injury biomarkers KIM-1 and NGAL. These findings highlight the potential of SGLT2 inhibitors in early tubular protection, offering a new therapeutic approach.
METHODS: A randomized controlled clinical study comprising 54 patients selected based on specific criteria was conducted. Patients were divided into an intervention group (empagliflozin, n = 27) and a control group (n = 27) and treated for 6 weeks. Tubular injury biomarkers KIM-1 and NGAL were assessed pre- and post-treatment.
RESULTS: Both groups demonstrated comparable baseline characteristics. Post-treatment, fasting and postprandial blood glucose levels decreased similarly in both groups. The intervention group exhibited better improvements in total cholesterol, low-density lipoprotein, and blood uric acid levels. Renal function indicators, including UACR and eGFR, showed greater enhancements in the intervention group. Significant reductions in KIM-1 and NGAL were observed in the intervention group.
CONCLUSIONS: Treatment with empagliflozin in type 2 diabetes patients with normoalbuminuria led to a notable decrease in tubular injury biomarkers KIM-1 and NGAL. These findings highlight the potential of SGLT2 inhibitors in early tubular protection, offering a new therapeutic approach.
摘要：
背景：2型糖尿病患者经常面临早期肾小管损伤，需要有效的治疗策略。本研究旨在评估SGLT2抑制剂依帕列净对正常白蛋白尿的2型糖尿病患者早期肾小管损伤生物标志物的影响。
方法：进行了一项随机对照临床研究，包括根据特定标准选择的54名患者。患者被分为干预组(empagliflozin，n=27）和对照组（n=27），治疗6周。在治疗前和治疗后评估肾小管损伤生物标志物KIM-1和NGAL。
结果：两组均表现出相当的基线特征。后处理,两组的空腹和餐后血糖水平下降相似.干预组表现出更好的总胆固醇改善，低密度脂蛋白，和血尿酸水平。肾功能指标,包括UACR和eGFR，在干预组中显示出更大的增强。在干预组中观察到KIM-1和NGAL的显著降低。
结论：在正常白蛋白尿的2型糖尿病患者中，依帕列净治疗导致肾小管损伤生物标志物KIM-1和NGAL显著降低。这些发现突出了SGLT2抑制剂在早期肾小管保护中的潜力。提供一种新的治疗方法。
方法：进行了一项随机对照临床研究，包括根据特定标准选择的54名患者。患者被分为干预组(empagliflozin，n=27）和对照组（n=27），治疗6周。在治疗前和治疗后评估肾小管损伤生物标志物KIM-1和NGAL。
结果：两组均表现出相当的基线特征。后处理,两组的空腹和餐后血糖水平下降相似.干预组表现出更好的总胆固醇改善，低密度脂蛋白，和血尿酸水平。肾功能指标,包括UACR和eGFR，在干预组中显示出更大的增强。在干预组中观察到KIM-1和NGAL的显著降低。
结论：在正常白蛋白尿的2型糖尿病患者中，依帕列净治疗导致肾小管损伤生物标志物KIM-1和NGAL显著降低。这些发现突出了SGLT2抑制剂在早期肾小管保护中的潜力。提供一种新的治疗方法。
